Selected article for: "AmphoB effect and IAV infection"
Author: Lin, Tsai-Yu; Chin, Christopher R.; Everitt, Aaron R.; Clare, Simon; Perreira, Jill M.; Savidis, George; Aker, Aaron M.; John, Sinu P.; Sarlah, David; Carreira, Erick M.; Elledge, Stephen J.; Kellam, Paul; Brass, Abraham L.
Title: Amphotericin B Increases Influenza A Virus Infection by Preventing IFITM3-Mediated Restriction
  • Cord-id: 10ynhrl3
  • Document date: 2013_11_21
    • ID: 10ynhrl3
    Snippet: The IFITMs inhibit influenza A virus (IAV) replication in vitro and in vivo. Here, we establish that the antimycotic heptaen, amphotericin B (AmphoB), prevents IFITM3-mediated restriction of IAV, thereby increasing viral replication. Consistent with its neutralization of IFITM3, a clinical preparation of AmphoB, AmBisome, reduces the majority of interferon’s protective effect against IAV in vitro. Mechanistic studies reveal that IFITM1 decreases host-membrane fluidity, suggesting both a possib
    Document: The IFITMs inhibit influenza A virus (IAV) replication in vitro and in vivo. Here, we establish that the antimycotic heptaen, amphotericin B (AmphoB), prevents IFITM3-mediated restriction of IAV, thereby increasing viral replication. Consistent with its neutralization of IFITM3, a clinical preparation of AmphoB, AmBisome, reduces the majority of interferon’s protective effect against IAV in vitro. Mechanistic studies reveal that IFITM1 decreases host-membrane fluidity, suggesting both a possible mechanism for IFITM-mediated restriction and its negation by AmphoB. Notably, we reveal that mice treated with AmBisome succumbed to a normally mild IAV infection, similar to animals deficient in Ifitm3. Therefore, patients receiving antifungal therapy with clinical preparations of AmphoB may be functionally immunocompromised and thus more vulnerable to influenza, as well as other IFITM3-restricted viral infections.

    Search related documents:
    Co phrase search for related documents
    • abelcet ambisome and low concentration: 1
    • absence presence and ach acetylcholine: 1
    • absence presence and actin cell: 1
    • absence presence and action mechanism: 1, 2, 3, 4, 5, 6
    • absence presence and adaptive immune system: 1
    • absence presence and live cell imaging cells: 1, 2
    • absence presence and loading control: 1, 2, 3
    • absence presence and location level: 1
    • absence presence and low concentration: 1, 2, 3
    • absence presence and low pathogenicity: 1
    • absence presence and luciferase gene: 1, 2, 3, 4
    • absence presence and lung carcinoma: 1
    • absence presence and lung carcinoma cell: 1
    • absence presence and lysosomal late endosomal: 1
    • absence red and live cell imaging cells: 1
    • absence red and loading control: 1